Confronta i metodi

	Studio Clinico multicentrico di Fase I	Analisi Dose-Risposta
Campo	Epidemiologia	Epidemiologia
Famiglia	Process / pipeline	Process / pipeline
Anno di origine	1970s–1980s (formalized in FDA Phase I guidance 1977; ICH E6 GCP 1996)	Conceptual roots 16th century; modern epidemiological application mid-20th century
Ideatore	Established through FDA regulatory guidance and ICH harmonization frameworks	Paracelsus (conceptual foundation); formalized by John Snow and later Bradford Hill
Tipo	Interventional clinical study design	Quantitative analytical method
Fonte seminale	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). ICH.	Rothman, K. J., Greenland, S., & Lash, T. L. (2008). Modern Epidemiology (3rd ed.). Lippincott Williams & Wilkins. ISBN: 978-0781755641
Alias	multisite Phase I trial, multi-institutional Phase I study, Phase I dose-escalation multicenter study, first-in-human multicenter trial	exposure-response analysis, concentration-response modeling, dose-response modeling, DRA
Correlati	6	4
Sintesi	A multicenter Phase I clinical trial is the first systematic administration of an investigational agent to humans, conducted simultaneously across two or more clinical sites. Its primary objectives are to characterize the safety and tolerability profile of the intervention, determine the maximum tolerated dose (MTD), and describe pharmacokinetic and pharmacodynamic behavior. Distributing enrollment across sites increases participant accrual speed and enhances the generalizability of early-phase safety data.	Dose-response analysis quantifies the relationship between the magnitude of an exposure (the dose) and the probability or rate of an outcome (the response). It is a core analytical strategy in epidemiology and toxicology, providing evidence that increasing exposure systematically increases — or decreases — the risk of disease. A demonstrated dose-response gradient is one of Bradford Hill's classic criteria supporting causal inference.